BioPh China 2016, hosted by UBM EMEA and China Chamber of Commerce of Medicines & Health Products Importers & Exporters and co-organized by UBM Sinoexpo, will be held on 21 – 23 June 2016 at Hall E2 in Shanghai New International Expo Centre.
The emerging industry of bio-medicine has become one of the strategic directions and focal development points of the pharmaceutical industry in coming years. This focus is supported by number of factors: recent completion of the Development of Pharmaceutical Industry for the Thirteenth Five-Year Plan Period in 2015, as well as by Made in China 2025 listing biomedicine represented by gene drugs, monoclonal antibody/protein drugs and vaccines as one of the ten key sectors to be develop in the future. The improvement of the overall technological content, added economic value of bio-medical industry, fostering of innovative drugs account to further contributing factors.
With biomedicine being one of the highlights at Nobel Prize and Prix Galien Awards, it is undoubted that biomedical industry has entered another fast growing golden age. As an annual professional biopharmaceutical technology event highly anticipated in Asian-Pacific region, BioPh China has received more focus from European and US countries over the past years. BioPh China will take place in 2016 providing a one-stop trade, exchange and learning platform for biopharmaceutical industry, bringing you the latest biomedical R&D achievements and technologies.
Up to now, domestic pharmaceutical giants such as Gan & Lee Pharmaceuticals, Tonghua Dongbao, Shenzhen Mellow Hope and Dongcheng Biochemicals have all confirmed their participation at BioPh China 2016, showcasing the most advanced R&D achievements, technologies and solutions of biomedical technical fields, including protein, antigen, polypeptide, enzyme, bioprocessing, antibody, biological agent, bio-manufacturing, cell biology, clinical trial, new drug R&D, genomics, genetics, personalized medicine, stem cell research, therapeutics, vaccine, biofuel, nanotechnology, biological information, biological information technology, and platform technology.
To enhance the communication and cooperation between Chinese biomedical enterprises and international enterprises, the 3rd BioPh Summit China, as the most important concurrently held onsite event, will gather industry-university-research elites and leaders in biomedical industry to discuss the course for future development of the industry. The summit will focus on the recent dynamics of Chinese and foreign policies, and global market opportunities and other strategic topics, as well as Chinese and foreign latest research achievements in recombinant protein drugs, antibodies and vaccines, to provide industry practitioners with an excellent platform for sharing industry information, R&D experience and case analysis. BioPh China 2016 will merge the new thinking and concepts into the Chinese biomedical industry through linkage of "exhibition" and "conference".
The emerging industry of bio-medicine has become one of the strategic directions and focal development points of the pharmaceutical industry in coming years. This focus is supported by number of factors: recent completion of the Development of Pharmaceutical Industry for the Thirteenth Five-Year Plan Period in 2015, as well as by Made in China 2025 listing biomedicine represented by gene drugs, monoclonal antibody/protein drugs and vaccines as one of the ten key sectors to be develop in the future. The improvement of the overall technological content, added economic value of bio-medical industry, fostering of innovative drugs account to further contributing factors.
With biomedicine being one of the highlights at Nobel Prize and Prix Galien Awards, it is undoubted that biomedical industry has entered another fast growing golden age. As an annual professional biopharmaceutical technology event highly anticipated in Asian-Pacific region, BioPh China has received more focus from European and US countries over the past years. BioPh China will take place in 2016 providing a one-stop trade, exchange and learning platform for biopharmaceutical industry, bringing you the latest biomedical R&D achievements and technologies.
Up to now, domestic pharmaceutical giants such as Gan & Lee Pharmaceuticals, Tonghua Dongbao, Shenzhen Mellow Hope and Dongcheng Biochemicals have all confirmed their participation at BioPh China 2016, showcasing the most advanced R&D achievements, technologies and solutions of biomedical technical fields, including protein, antigen, polypeptide, enzyme, bioprocessing, antibody, biological agent, bio-manufacturing, cell biology, clinical trial, new drug R&D, genomics, genetics, personalized medicine, stem cell research, therapeutics, vaccine, biofuel, nanotechnology, biological information, biological information technology, and platform technology.
To enhance the communication and cooperation between Chinese biomedical enterprises and international enterprises, the 3rd BioPh Summit China, as the most important concurrently held onsite event, will gather industry-university-research elites and leaders in biomedical industry to discuss the course for future development of the industry. The summit will focus on the recent dynamics of Chinese and foreign policies, and global market opportunities and other strategic topics, as well as Chinese and foreign latest research achievements in recombinant protein drugs, antibodies and vaccines, to provide industry practitioners with an excellent platform for sharing industry information, R&D experience and case analysis. BioPh China 2016 will merge the new thinking and concepts into the Chinese biomedical industry through linkage of "exhibition" and "conference".
